...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Could it be

jbuffet ... that makes sense. Plus, it is always good to show you have a plan/support to "go it alone" while negotiating. But competition between BP's is good.

This group that Zenith has engaged is doubly interesting because it is huge, with lots of money. Wondering whether this partnership could bring funding/financing potentially? If nothing else, it is good to have people who understand how to make money, in the house now lol ... (take notes DM).

Looks like the RVX/Eversana partnering play call, but on steroids. 

Most of my interest is in RVX rather than Zenith (a small holding), but I gotta figure that whatever is good for Zenith, can't be bad for RVX. So, go Zenith!!

Share
New Message
Please login to post a reply